3 results
Primary Objective: The primary objective is to investigate whether EUS-TCB had an added value on EUS-FNA alone. Secondary Objective(s): The secondary objective is to study whether EUS-TCB does not have a higher complication rate than EUS-FNA alone.
To determine a safe dose combination of carboplatin-cyclophosphamide combined with atezolizumab fixed dose in advanced breast cancer and gynaecologic cancer (ovarian, cervical and endometrial cancer).
Primary objective:To evaluate the efficacy of cobolimab + dostarlimab + docetaxel relative to docetaxel alone in participants with advanced NSCLC who have progressed on prior anti-PD-(L)1 therapy andChemotherapy.To evaluate the efficacy of…